Pitarokoili Kalliopi, Kohle Felix, Motte Jeremias, Fatoba Oluwaseun, Pedreiturria Xiomara, Gold Ralf, Yoon Min-Suk
Department of Neurology, St. Josef Hospital, Ruhr-University of Bochum, Germany.
Department of Neurology, St. Josef Hospital, Ruhr-University of Bochum, Germany.
J Neuroimmunol. 2017 Aug 15;309:58-67. doi: 10.1016/j.jneuroim.2017.05.008. Epub 2017 May 19.
Intravenous human immunoglobulins dominate in the treatment of autoimmune neuropathies. We introduce intrathecal application as a new option for experimental autoimmune neuritis in Lewis rats. After immunisation with neuritogenic P2 peptide, we show a therapeutic and preventive effect of intrathecal human immunoglobulins (5-40mg/kg) on clinical and electrophysiological neuritis signs. Histology corroborated a lower degree of inflammation, demyelination, ICAM-1-dependent blood-nerve-barrier permeability and complement activation in the sciatic nerve. After preventive application, immunoglobulins induced a Th2 cytokine shift in the peripheral nerves already before clinical neuritis signs. Intrathecal immunoglobulin application could be a novel immunomodulatory option for autoimmune neuropathies.
静脉注射用人免疫球蛋白在自身免疫性神经病的治疗中占主导地位。我们介绍鞘内注射作为Lewis大鼠实验性自身免疫性神经炎的一种新选择。在用致神经炎的P2肽免疫后，我们展示了鞘内注射人免疫球蛋白（5 - 40mg/kg）对临床和电生理神经炎体征的治疗和预防作用。组织学证实坐骨神经中炎症、脱髓鞘、ICAM - 1依赖性血神经屏障通透性和补体激活程度较低。预防性应用后，免疫球蛋白在临床神经炎体征出现之前就已在外周神经中诱导了Th2细胞因子转变。鞘内注射免疫球蛋白可能是自身免疫性神经病的一种新型免疫调节选择。
